natgillin/translations-raw huggingface dataset:
Guidelines for CAP are more complex than those for other respiratory infections as they take into account several criteria like age and / or comorbidities, severity of the disease and the management as out- or in-patients. 
Smernice za ZBP so zapletenejše od smernic za druge okužbe dihal, saj upoštevajo več meril, kot so starost in/ali sočasne bolezni, resnost bolezni in bolnišnično ali ambulantno zdravljenje.
In the European guidelines, levofloxacin is recommended as an alternative antibiotic, with the possibility of use as a first-line agent in countries with a high level of clinically relevant resistance to the first-line drugs. 
V evropskih smernicah je levofloksacin priporočen kot alternativni antibiotik, ki ga je mogoče uporabljati kot sredstvo prve izbire v državah z visoko ravnjo klinično pomembne odpornosti proti zdravilom prve izbire.
Therefore, on the basis of the efficacy data provided by the MAH for ABS, Pharmacokinetic/Pharmacodynamic considerations and the extensive risk profile of levofloxacin, it was agreed that the wording for the ABS indication should be in line with the wording agreed for other the fluoroquinolon agents. 
Zato je bil na podlagi podatkov o učinkovitosti, ki jih je predložil imetnik dovoljenja za promet z zdravilom za ABS, farmakokinetičnih/farmakodinamičnih ugotovitev ter obsežnega profila o tveganjih, povezanih z levofloksacinom, sprejet dogovor, da mora biti besedilo za indikacijo ABS skladno z besedilom, ki je bilo odobreno za druge fluorokinolone.
The proposal presented by the MAH reflected the latest scientific information including Core Safety Information (harmonisation of the safety sections of the SmPC: 4.3 to 4.9) agreed in April 2011 as an outcome of the PSUR worksharing, recent safety reviews of fluoroquinolones and new worldwide data on safety of fluoroquinolon. 
Predlog, ki ga je predstavil imetnik dovoljenja za promet, je vseboval najnovejše znanstvene informacije, vključno z bistvenimi informacijami o varnosti (uskladitev poglavij o varnosti v povzetku glavnih značilnosti zdravila: od 4.3 do 4.9), ki so bile sprejete aprila 2011 kot izid projekta z deljenim delom PSUR (z zadnjimi podatki dopolnjeno redno poročilo o varnosti zdravila), najnovejših pregledov varnosti fluorokinolonov in novih podatkov o varnosti fluorokinolona z vsega sveta.
Due to the high spontaneous cure rates in this kind of infection, data showing superiority over placebo or comparators in more severe ABS are considered as a prerequisite to outweigh the extensive risks and to keep the benefits and risks balanced only in situations where beta-lactams, doxycycline or macrolides cannot be used for any reason or failed. 
Zaradi visokih ravni spontane ozdravitve pri tej vrsti okužbe so podatki, ki prikazujejo prednost zdravila v primerjavi s placebom ali primerljivimi zdravili pri hujših primerih ABS, upoštevani kot predpogoj, ki odtehta obsežna tveganja in ki ohranja koristi in tveganja v ravnovesju le v primerih, kadar zaradi kakršnega koli razloga ni mogoče uporabiti betalaktamov, doksiciklina ali makrolidov ali pa je bilo zdravljenje z njimi neuspešno.
The MAH agreed that the harmonised wording for levofloxacin should also be in line with wording for other fluoroquinolones. 
Imetnik dovoljenja za promet je soglašal, da mora biti usklajeno besedilo za levofloksacin skladno tudi z besedilom za druge fluorokinolone.
This study included only acute cystitis patients and not uncomplicated pyelonephritis, even those might be encompassed within the classification of “uncomplicated UTI”. 
Študija je vključevala le bolnice z akutnim cistitisom in ne tistih z nezapletenim pielonefritisom, tudi če bi lahko bile zajete v klasifikaciji „nezapletene okužbe sečil“.
• The committee reviewed the data submitted by the MAH from the existing clinical studies, the pharmacovigilance data and the published literature justifying the proposed harmonisation of the product information 
• Odbor je pregledal podatke iz obstoječih kliničnih študij, podatke o farmakovigilanci in podatke iz objavljene literature, ki jih je predložil imetnik dovoljenja za promet z zdravilom in ki upravičujejo predlagano uskladitev informacij o izdelku.
The European Respiratory Society guideline (ERS, 2005) proposes levofloxacin as an alternative antibiotic for both hospital and community management of AECB with no risk factors for P. aeruginosa. 
Smernice Evropskega respiratornega društva (European Respiratory Society - ERS, 2005) predlagajo levofloksacin kot alternativni antibiotik za bolnišnično in domače zdravljenje AEKB brez dejavnikov tveganja za P. aeruginosa.
It is noted that fluoroquinolones, including levofloxacin are not recognised as reference treatment for staphylococci and streptococci. 
Fluorokinoloni, vključno z levofloksacinom, niso opredeljeni kot referenčno zdravljenje proti stafilokokom in streptokokom.
The warning on exacerbation of myasthenia gravis included in the CSP was revised based on the cumulative safety review presented by the MAH during this referral procedure. 
Opozorilo glede poslabšanja miastenije gravis, ki je bilo vključeno v osnovni varnostni profil, je bilo revidirano na podlagi kumulativnega varnostnega pregleda, ki ga je predstavil imetnik dovoljenja za promet v času tega napotitvenega postopka.
In the EU the approval of levofloxacin was first granted in the United Kingdom (UK) in 1997 followed by eleven other Member States (MS): Austria, Belgium, Denmark, Finland, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal and Spain through the mutual recognition procedure (MRP) with UK as reference MS. Tavanic is also approved nationally in thirteen other MS: Bulgaria, Cyprus, Czech Republic, Estonia, France, Greece, Hungary, Lithuania, Malta, Poland, Slovakia, Slovenia and Sweden. 
V EU je bil levofloksacin najprej odobren v Združenem kraljestvu leta 1997, nato pa še v enajstih državah članicah: v Avstriji, Belgiji, na Danskem, Finskem, v Nemčiji, na Irskem, v Italiji, Luksemburgu, na Nizozemskem, Portugalskem in v Španiji po postopku z medsebojnim priznavanjem, v katerem je bilo Združeno kraljestvo referenčna država članica.
Annex II Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisations 
Znanstveni zaključki in podlaga za spremembo pogojev dovoljenj za promet z zdravilom
Hence, Tavanic was included in the list of products for PI harmonisation, drawn up by the CMD(h), in accordance with Article 30(2) of Directive 2001/83/EC, as amended. 
Zato je bilo zdravilo Tavanic vključeno na seznam zdravil za uskladitev informacij o zdravilu, ki ga je sestavila Skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila v humani medicini (CMD(h)) v skladu s členom 30(2) Direktive 2001/83/ES, kakor je bila spremenjena.
Considering the extent of the harmonisation of the PL a Readability Testing was agreed to be submitted after the adoption of this referral procedure. 
Glede na obseg usklajevanja navodila za uporabo je bilo dogovorjeno, da bo po sprejetju napotitvenega postopka predložen preskus razumljivosti besedila.
Chronic bacterial prostatitis (or ‘prostatitis') is an approved indication for levofloxacin in all MS with exception for two MS. 
Kronični bakterijski prostatitis (ali „prostatitis“) je odobrena indikacija za levofloksacin v vseh državah članicah razen dveh.
Levofloxacin has a broad in vitro antibacterial spectrum that includes Gram-positive organisms such as Streptococcus pneumoniae regardless of resistance phenotype, methicillin-susceptible Staphylococcus aureus and Streptococci spp., fastidious Gram-negative bacteria such as Haemophilus influenzae, Moraxella catarrhalis and Enterobacteriaceae such as Escherichia coli and Klebsiella spp., and organisms responsible for atypical infection such as Legionella, Mycoplasma and Chlamydophila. 
Levofloksacin ima širok spekter protibakterijskega delovanja in vitro, ki vključuje po Gramu pozitivne organizme, kot so Streptococcus pneumoniae, ne glede na fenotip odpornosti, za meticilin občutljivi Staphylococcus aureus in Streptococci spp., občutljive po Gram negativne bakterije, kot so Haemophilus influenzae, Moraxella catarrhalis in Enterobacteriaceae, kot sta Escherichia coli in Klebsiella spp., ter organizmi, ki povzročajo atipične okužbe, npr. Legionella, Mycoplasma in Chlamydophila.
With regards the contra indication in patients with glucose-6phosphate dehydrogenase (G6PD) deficiency it was agreed to keep this relative contra indication in the warning section of the SmPC as it was approved in all but one MS. 
V zvezi s kontraindikacijo pri bolnikih s pomanjkanjem glukoza-6-fosfat-dehidrogenaze (G6PD) so se dogovorili, da bo ta relativna kontraindikacija ostala v poglavju z opozorili v povzetku glavnih značilnosti zdravila, ker je bila odobrena v vseh, razen v eni državi članici.
The warning under sub-heading “Interference with laboratory tests” was updated mainly to include sentence on M. tuberculosis, which is considered class labelling and which is included in the Company Core Data Sheet (CCDS). 
Opozorilo pod podnaslovom „Vpliv na laboratorijske teste“ je bilo posodobljeno tako, da vsebuje stavek o M. tuberculosis, ki naj bi označeval ves razred in ki je vključen v seznam osnovnih podatkov podjetja (CCDS).
In addition, information on the hepatotoxicity was complemented to refer that reported cases of jaundice and severe liver injury with levofloxacin, include cases with fatal acute liver failure, primarily in patients with severe underlying diseases. 
Poleg tega so bile informacije o hepatotoksičnosti dopolnjene tako, da navajajo prijavljene primere zlatenice in hude poškodbe jeter z levofloksacinom ter vključujejo primere akutne odpovedi jeter s smrtnim izidom, predvsem pri bolnikih s hudimi osnovnimi boleznimi.
Grounds for the variation to the terms of the marketing authorisations 
Razlogi za spremembo pogojev dovoljenj za promet z zdravilom
The committee noted that for another fluoroquinolon agent a placebo-controlled study failed to show superiority over placebo in terms of clinical response. 
Odbor je opozoril, da študija z drugo fluorokinolonsko učinkovino, nadzorovana s placebom, ni dokazala prednosti zdravila v primerjavi s placebom, kar zadeva klinični odziv.
The harmonised warning on dysglycaemia was further amended in light of the recent reported cases of hypoglycaemic coma with fluoroquinolon agents. 
Usklajeno opozorilo o disglikemiji je bilo nadalje spremenjeno z vidika nedavno prijavljenih primerov hipoglikemične kome pri uporabi fluorokinolonskih učinkovin.
In clinical practice, the most commonly prescribed antibiotics for sinusitis are betalactams (amoxicillin with or without clavulanic acid, oral second and third-generation cephalosporins), macrolides, and antipneumococcal fluoroquinolones. 
V klinični praksi so najpogosteje predpisani antibiotiki za sinusitis betalaktami (amoksicilin s klavulansko kislino ali brez nje, peroralni cefalosporini druge in tretje generacije), makrolidi in antipnevmokokni fluorokinoloni.
Tavanic (levofloxacin) is a synthetic antibacterial agent of the fluoroquinolone class and is the S(-) enantiomer of the racemic drug substance ofloxacin. 
Tavanic (levofloksacin) je sintetično protibakterijsko sredstvo iz razreda fluorokinolonov in je S(-) enantiomer racematne snovi ofloksacina.
The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) endorses the “Guideline for the management of adult lower respiratory tract infections” that establishes quinolones as second-choice treatment in case of clinically relevant pneumococcal resistance against amoxicillin and tetracyclines, or major intolerance. 
Evropska zveza za klinično mikrobiologijo in infekcijske bolezni (European Society of Clinical Microbiology and Infectious Diseases - ESCMID) je sprejela „Smernice za obvladovanje okužb spodnjih dihal pri odraslih“, ki določajo kinolone za zdravljenje druge izbire v primeru klinično pomembne odpornosti pnevmokokov na amoksicilin in tetracikline ali v primeru pomembne netolerance.
A cross reference to the warning sections with regards resistance patterns was agreed. 
Dogovorili so se tudi za navzkrižni sklic na poglavje z opozorili o vzorcih odpornosti.
To more concisely define the role of levofloxacin in this indication, the MAH initially proposed the following harmonised wording for the tablets and IV solution: 
Za jasnejšo opredelitev vloge levofloksacina pri tej indikaciji je imetnik dovoljenja za promet z zdravilom sprva predlagal naslednje usklajeno besedilo za tablete in i.v.
Betalactams, macrolides and antipneumococcal fluoroquinolones are the most commonly used antibiotics for the treatment of CAP, as monotherapy or in combination, depending on the patient risks and the severity. 
Betalaktami, makrolidi in antipnevmokokni fluorokinoloni so najpogosteje uporabljeni antibiotiki za zdravljenje ZBP kot monoterapija ali v kombinaciji, odvisno od tveganj za bolnika in od resnosti bolezni.
• The committee considered the identified divergences for Tavanic and associated names regarding the therapeutic indications and the posology and method of administration sections, as well as in the remaining sections of the SmPCs 
• Odbor je upošteval ugotovljena razhajanja za zdravilo Tavanic in povezana imena v poglavjih o terapevtskih indikacijah, odmerjanju in načinu uporabe ter v preostalih poglavjih povzetkov glavnih značilnosti zdravila.
In conclusion, based on the assessment of the MAH proposal and responses and following the discussions of the committee, the CHMP adopted harmonised sets of Product Information documents for the film-coated tablets and solution for infusion of Tavanic and associated names, taking into account the pharmaceutical forms. 
Na podlagi ocene predloga in odzivov imetnika dovoljenja za promet z zdravilom ter po razpravah v odbor CHMP je ta sprejel usklajene sklope dokumentov z informacijami o zdravilu za filmsko obložene tablete in raztopino za infundiranje Tavanic in povezana imena, pri čemer je upošteval farmacevtske oblike.
For the majority of the approved indications, the posology was overall harmonised in practically all MS, the MAH proposed the following dosing recommendations: 
Za večino odobrenih indikacij je odmerjanje v splošnem usklajeno v praktično vseh državah članicah, imetnik dovoljenja za promet z zdravilom pa je predlagal naslednja priporočila za odmerjanje:
Since uUTI is defined as a presence of episodes of acute cystitis and acute pyelonephritism, the MAH proposed to harmonise this indication for “uncomplicated cystitis” to better reflect the patients population included in the study. 
Ker je nezapletena okužba sečil opredeljena kot prisotnost epizod akutnega cistitisa in akutnega pielonefritizma, je imetnik dovoljenja za promet z zdravilom predlagal uskladitev te indikacije v „nezapleteni cistitis“, ki bi bolje odražala populacijo bolnic, zajetih v to študijo.
The warning on hepatobiliary disorders was updated to reflect the current evidence suggesting a causal relationship between levofloxacin and hepatotoxicity which may result in a fatal outcome. 
Opozorilo o boleznih jeter, žolčnika in žolčevodov je bilo posodobljeno tako, da odraža trenutne dokaze, ki kažejo na vzročno razmerje med levofloksacinom in hepatotoksičnostjo, ki ima lahko tudi smrten izid.
A warning on severe bullous reactions was proposed by the MAH due to the seriousness of these reactions and considering that bullous eruptions were already included in section 4.8 of the SmPC. 
Imetnik dovoljenja za promet z zdravilom je predlagal opozorilo o hudih buloznih reakcijah zaradi resnosti teh reakcij in z upoštevanjem, da so bile bulozni izbruhi že zajeti v poglavju 4.8 povzetka glavnih značilnosti zdravila.
Precaution for use in inhalation of anthrax was moved from section 5.1 to this section to warn prescribers on the need to refer to further guidance in this situation. 
Previdnostni ukrep za inhalacijski vranični prisad je bil premaknjen iz poglavja 5.1 v to poglavje in opozarja zdravnike, ki predpisujejo zdravilo, na potrebo po vpogledu v nadaljnjo dokumentacijo v zvezi s to okoliščino.
The proposed harmonised lower dosage for AECB and for cSSTIs of 250 mg was further discussed in light of pharmacokinetic/pharmacodinamic profile of levofloxacin, the nature of infection and the most probable causative bacterial agent. 
Predlagani usklajeni manjši odmerek za AEKB in zapletene okužbe kože in mehkih tkiv, 250 mg, je bil nadalje obravnavan z vidika farmakokinetičnega/farmakodinamičnega profila levofloksacina, narave okužbe in najverjetnejše bakterije povzročiteljice.
Current treatment guidelines usually recommend antipneumococcal fluoroquinolones for severe ABS, or where previous treatment has failed, or for infections involving resistant pneumococci. 
Trenutne smernice za zdravljenje običajno priporočajo antipnevmokokne fluorokinolone za hujše primere akutnega bakterijskega sinusitisa oz. primere, pri katerih je bilo predhodno zdravljenje neuspešno, ali za okužbe, ki vključujejo odporne pnevmokoke.
Overall, levofloxacin showed to be at least as effective as other treatment recommended as first-line options, e.g. intravenous ceftriaxone and/or oral cefuroxime axetil plus macrolides and also to amoxicillin/clavulanic acid. 
V splošnem je bilo za levofloksacin dokazano, da je vsaj tako učinkovit kot druga zdravila, ki so priporočena kot prva izbira - npr. intravenski ceftriakson in/ali peroralni cefuroksim aksetil z makrolidi ter amoksicilin/klavulanska kislina.
As a fluoroquinolone antibacterial agent, levofloxacin inhibits DNA synthesis by acting on the DNA/DNA-gyrase complex and topoisomerase IV. 
Levofloksacin kot fluorokinolonsko protibakterijsko sredstvo zavira tvorbo DNK tako, da deluje na kompleks giraze DNK/DNK in topoizomerazo IV.
• Complicated skin and soft tissue infections 
• zapletene okužbe kože in mehkih tkiv
Tavanic solution for infusion is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): 
Raztopina za infundiranje Tavanic je indicirana pri odraslih za zdravljenje naslednjih okužb (glejte poglavji 4.4 in 5.1):
Further amendment was agreed with regards the duration of treatment for pyelonephritis and for cUTIs to be in line with the European Association of Urology (EAU) guidelines 2010 recommendations for levofloxacin treatment duration of 7-10 days for acute uncomplicated pyelonephritis, and 7-14 days (IV followed by possible oral switch) for severe cases (EAU guidelines 2010). 
Dogovorili so se o nadaljnjih spremembah trajanja zdravljenja za pielonefritis in zapletene okužbe sečil, ki naj bo skladno s priporočili smernic Evropskega združenja za urologijo (European Association of Urology - EAU) iz leta 2010 o trajanju zdravljenja z levofloksacinom 7-10 dni za akutni nezapleteni pielonefritis in 7-14 dni (i.v.
The warning on the superinfection was amended in line with the standard wording on this point included in the PI for all antibacterial agents. 
Opozorilo o superinfekciji je bilo prilagojeno v skladu z ustreznim standardnim besedilom, ki je vključeno v informacije o zdravilu za vsa protibakterijska sredstva.
Complicated UTIs (cUTIs) including pyelonephritis (PN), has been submitted and approved in all except one EU MS, where only the indication for acute pyelonephritis (APN) was approved. 
Zapletene okužbe sečil, vključno s pielonefritisom, so bile predložene in odobrene v vseh državah članicah EU razen v eni, kjer je bila odobrena samo indikacija za akutni pielonefritis.
Tavanic is available as film coated tablets (250 mg and 500 mg) and as solution for infusion (5mg/ml in presentations of 250mg/50ml and 500mg/100ml). 
Zdravilo Tavanic je na voljo v obliki filmsko obloženih tablet (250 mg in 500 mg) in kot raztopina za infundiranje (5 mg/ml v pakiranjih po 250 mg/50 ml in 500 mg/100 ml).
Chronic bacterial prostatitis 
Kronični bakterijski prostatitis
Uncomplicated cystitis (see section 4.4) 
• nezapleteni cistitis (glejte poglavje 4.4)
This strength and presentation was linked with the indication for HAP which the MAH did not claim for in this harmonisation procedure. 
Ta jakost in pakiranje sta bila povezana z indikacijo za bolnišnično pljučnico, ki je imetnik dovoljenja za promet z zdravilom ni uveljavljal v tem postopku usklajevanja.
Uncomplicated UTIs indication has been approved for 250 mg tablets of levofloxacin as in all MS except in three MS. 
Indikacija za nezapletene okužbe sečil je bila odobrena za 250 mg tablete levofloksacina v vseh državah članicah, razen v treh.
The CHMP noted the MAH proposal for an harmonised text for this section. 
Odbor CHMP je preučil predlog imetnika dovoljenja za promet z zdravilom za usklajeno besedilo tega poglavja.
Three pivotal studies supported this indication, granted in the EU since 1997. 
To indikacijo, ki je v EU odobrena od leta 1997, so podprle tri ključne študije.
Therefore, the recommended dose for AECB and for cSSTIs were amended accordingly i.e. 250 mg once daily is deleted. 
Zato sta bila priporočena odmerka za AEKB in zapletene okužbe kože in mehkih tkiv ustrezno prilagojena, tako da je bil odmerek 250 mg enkrat dnevno izbrisan.
The CHMP noted the MAH proposal for this section and further agreed on a number of revisions. 
Odbor CHMP je proučil predlog imetnika dovoljenja za promet z zdravilom za to poglavje in se strinjal s številnimi spremembami.
This indication is approved for levofloxacin tablets in all MS identified above via nationally or mutual recognition procedure (MRP) with exception of one MS. 
Ta indikacija je odobrena za tablete levofloksacina v vseh državah članicah, ki so navedene zgoraj, z nacionalnim postopkom ali postopkom z medsebojnim priznavanjem, razen v eni državi članici.
Therefore a specific warning for the pattern of resistance to fluoroquinolones resistance to E. coli is included in section 4.4 of the SmPC. 
Zato je v poglavje 4.4 povzetka glavnih značilnosti zdravila vključeno posebno opozorilo na vzorec odpornosti E. coli proti fluorokinolonom.
• ABS (tablets only): 500 mg once daily for 10-14 days of treatment; 
• ABS (samo tablete): 500 mg enkrat dnevno za 10-14 dni zdravljenja;
In this regard, it is noted that the 500 mg dosage given once daily by oral route allow to reach a plasmatic peak concentration (Cmax) as of 5 to 6 mg/l and a Cmax/MIC ratio of 10-12 and an AUC of approximately 50 mg.h/l corresponding to an AUC/MIC ratio as of 50-100. 
5 do 6 mg/l in razmerja Cmaks./MIK 10-12 ter vrednosti AUC približno 50 mg.h/l, kar ustreza razmerju AUC/MIK 50-100.
The MAH voluntarily withdrew the marketing authorisation (MA) for the 750 mg film coated tablets and varied the terms of the MAs for the solution for infusion to remove the 150 ml presentation during this referral procedure. 
Imetnik dovoljenja za promet z zdravilom je v času tega napotitvenega postopka prostovoljno umaknil dovoljenje za filmsko obložene tablete 750 mg in spremenil pogoje dovoljenja za promet z zdravilom za raztopino za infundiranje, tako da je umaknil pakiranje 150 ml.
Five additional studies since then have been performed by the MAH. 
Od tedaj je imetnik dovoljenja za promet izvedel še pet dodatnih študij.
All MRP SmPCs list “Acute bacterial sinusitis” in the indication section and also specified “(adequately diagnosed according to national and/or local guidelines on the treatment of respiratory tract infections)”. 
Vsi povzetki glavnih značilnosti zdravila v postopku z medsebojnim priznavanjem navajajo „akutni bakterijski sinusitis“ v poglavju z indikacijami in specifično „(ustrezno diagnosticiran v skladu z nacionalnimi in/ali lokalnimi smernicami za zdravljenje okužb dihal)“.
Acute exacerbation of chronic bronchitis (AECB) 
Akutna eksacerbacija kroničnega bronhitisa (AEKB)
The evidence was provided by the MAH including a cumulative review of all fatal cases due to hepatibilary disorders. 
Dokaze je predložil imetnik dovoljenja za promet z zdravilom, vključno s kumulativnim pregledom vseh smrtnih primerov zaradi bolezni jeter, žolčnika in žolčevodov.
In addition the warning section of the SmPC now refers to the co-resistance of the fluroquinolones including levofloxacin to MRSA. 
Poleg tega poglavje z opozorili v povzetku glavnih značilnosti zdravila zdaj navaja soodpornost MRSA proti fluorokinolonom, vključno z levofloksacinom.